Insurance Denied Your Cancer Treatment? How to Appeal in 2026

First, take a breath: a denial is a starting point, not the end

If you are reading this after an insurance denial for cancer treatment, you are likely frightened, exhausted, and worried about both your health and your finances. That is a completely understandable place to be, and the stress you are feeling has a name that researchers and oncologists use: financial toxicity. Studies through 2025 report that financial hardship affects a very large share of U.S. cancer patients, including people who are well insured. It is not a personal failing. It is a well-documented feature of how cancer care is paid for in this country.

Here is the practical reassurance: an insurance denial is often a first answer, not a final one. Insurers deny for many reasons, and a large share of denials are reversed on appeal, especially in oncology where guidelines, off-label use, and newer therapies are involved. You do not have to accept the denial at face value, and you do not have to fight it alone. Your oncology team, the cancer center’s financial navigator, and nonprofit patient-advocacy groups can help you build the appeal.

This guide walks through the rights that protect you, why certain cancer denials happen, the specific counters that tend to work, and a step-by-step appeal process. Everything here reflects the rules as of 2026. Where protections vary by state or plan type, we say so, because the details genuinely matter.

Your core rights as a cancer patient in 2026

Under the Affordable Care Act, non-grandfathered health plans (Marketplace plans and most individual and employer plans) give cancer patients several core protections that are all in effect in 2026. Knowing these rights helps you recognize when a denial or a bill may be wrong.

• No annual or lifetime dollar limits on essential health benefits. An ACA-compliant plan cannot put a dollar ceiling on your covered cancer care, so there is no dollar cap you can hit mid-treatment for essential health benefit items (source: HHS and HealthCare.gov).
• An annual out-of-pocket maximum on in-network essential health benefits. For 2026, HHS set the cap at $10,600 for self-only coverage and $21,200 for a family. Once you reach your plan’s out-of-pocket max, the plan pays 100 percent of covered in-network essential health benefits for the rest of the year. Note that many employer plans set lower limits, and the cap protects in-network covered care, so out-of-network care and non-covered items may not count toward it.
• Guaranteed issue and no pre-existing-condition exclusions. An ACA-compliant plan cannot deny you, delay you, or charge you more because you have or had cancer.
• Clinical-trial routine-cost coverage (ACA Section 2709). Effective for plan years since January 1, 2014, non-grandfathered plans must not deny your participation in an approved trial, must cover the routine patient costs (the standard visits, labs, imaging, and hospital care you would get anyway), and must not discriminate against you for taking part. The plan does not have to pay for the investigational item itself (the trial sponsor often does), for data-collection-only services, or for care inconsistent with the standard of care. Patients are sometimes wrongly told that joining a trial voids their normal coverage. It does not, and a routine-cost denial tied to a trial is worth appealing (source: CMS ACA Implementation FAQs Set 15; PHSA Section 2709).
• Coverage of off-label anticancer drugs supported by compendia. For Medicare, off-label use must be covered when at least one CMS-recognized compendium supports it, including the NCCN Drugs and Biologics Compendium (source: CMS article A58113). Many state laws impose a similar requirement on state-regulated commercial plans, though these mandates vary by state and generally do not reach self-funded ERISA employer plans.
• Oral chemotherapy parity in most states. As of 2026, 43 states plus D.C. require oral anticancer drugs to be covered on terms no less favorable than IV or injected chemo (Oregon was first). State parity laws generally do not apply to self-funded ERISA employer plans (which cover roughly 6 in 10 workers with employer coverage), Medicare, or Medicaid. A federal Cancer Drug Parity Act (H.R.4101 in the 119th Congress) has been introduced but is not law as of 2026.

Why proton, experimental, and off-label denials happen (and how to counter them)

Some cancer denials are essentially arguments about evidence and cost, and they follow predictable patterns. Understanding the pattern is the first step to answering it point by point.

Proton beam therapy is a good example. It is a form of radiation that can spare surrounding healthy tissue, it has been in clinical use for decades, it uses FDA-cleared devices, and it is offered at more than 40 major U.S. cancer centers. It is considered standard for certain cancers, including many pediatric tumors and some skull-base, ocular, and central-nervous-system cases. Even so, insurers deny a large share of initial proton requests, commonly labeling it experimental, investigational, or not medically necessary, often arguing that conventional photon or IMRT radiation would work as well for that specific cancer. Newer treatments, including some targeted therapies, certain CAR T-cell and cellular therapies, newer radiation techniques, and novel drug combinations, draw similar denials because insurer medical-necessity criteria can lag behind clinical adoption.

Off-label use draws denials too, and this one surprises many patients. Using a cancer drug off-label, meaning for a cancer type or combination not listed on the FDA-approved label, is standard, evidence-based oncology practice, not experimental care. The strongest counter to an off-label denial is a listing in the NCCN Drugs and Biologics Compendium (often with a category-of-evidence rating) and, where relevant, supporting peer-reviewed studies, submitted with your oncologist’s letter. Ask your oncologist or the cancer center’s financial navigator whether your specific use has an NCCN Compendium listing, because that citation is what many appeals turn on.

• Get the plan’s exact clinical policy and criteria in writing so your team can respond point by point.
• Have the treating physician write a letter of medical necessity explaining why this treatment is needed for you specifically. For proton therapy, that might mean tumor location next to critical organs, prior radiation, pediatric status, or a documented dosimetric comparison plan showing protons meaningfully reduce dose to healthy tissue.
• Cite NCCN guidelines and Compendium listings, FDA labeling where relevant, and specialty-society guidance such as ASTRO’s model coverage policy for radiation, where they support the treatment.
• Request a peer-to-peer review between your oncologist and the plan’s medical director.
• If still denied, pursue the internal appeal and then independent external review. Framing the appeal around this patient’s specific medical facts tends to be more persuasive than general arguments (sources: NCCN; ASTRO model policy; National Association for Proton Therapy denials and appeals toolkit).

Common denial reasons and how to answer each one

Denial letters use a handful of recurring phrases. Find the phrase that matches your letter and use the paired counter as a starting point for your appeal.

• “Not medically necessary.“ The plan says the treatment does not meet its clinical criteria for your situation. Counter with an oncologist letter tying the treatment to your specific facts plus NCCN or guideline citations, and request a peer-to-peer review.
• “Experimental or investigational.“ Often applied to proton therapy, some cellular and CAR-T therapies, and newer techniques. Counter by documenting the treatment’s established status (FDA clearance, NCCN listing, ASTRO or other specialty guidance) and the medical reason it is needed for you.
• “Off-label or not FDA-approved for your cancer.“ Very common in oncology. Counter with an NCCN Drugs and Biologics Compendium listing and peer-reviewed literature. Medicare and many state laws require coverage of compendia-supported off-label anticancer uses.
• “Out-of-network provider or center.“ The specialist or NCI-designated center is outside the network. Counter by requesting a network-adequacy or gap exception when no in-network provider can deliver the needed expertise, and check your continuity-of-care rights.
• “Prior authorization or step therapy not met.“ The drug or procedure needed advance approval, or the plan wants a cheaper option first. Counter by submitting the prior authorization with clinical justification and, where appropriate, a step-therapy medical exception explaining why the required first drug is unsafe or ineffective for you.
• “Site-of-care or billing and coding issue.“ The plan wants care at a lower-cost setting, or a claim was coded or processed incorrectly. Ask for the specific site-of-care policy, and if a bill looks wrong, have the provider verify the codes and resubmit, since it may be a correctable error rather than a true denial.

The appeal process, step by step

You do not need to do all of this in one day, and much of it can be led by your oncology team and the cancer center’s financial navigator or patient advocate. Work through the steps in order, and keep a log of every call with the date, the name of the person you spoke with, and the reference number.

• 1. Get the denial in writing and pin down the exact reason. Identify the specific label (not medically necessary, experimental, off-label, out-of-network, no prior authorization) and the clinical policy or criteria the plan used. You have the right to your plan’s specific criteria and to the records used to decide. Note the appeal deadline on the letter.
• 2. Ask your oncologist for a letter of medical necessity. It should tie the treatment to your specific medical facts and cite supporting evidence: NCCN guidelines and Compendium, FDA labeling where relevant, and peer-reviewed studies. The financial navigator or a patient advocate can often help assemble it.
• 3. Request a peer-to-peer review. This is a direct conversation between your treating physician and the plan’s medical director. Many denials are reversed at this stage once the clinical picture is explained.
• 4. File the plan’s internal appeal before the deadline. Attach the medical-necessity letter, the guideline and compendium citations, and any records the criteria call for. Keep copies of everything.
• 5. If it is urgent, request an expedited appeal. If waiting could seriously jeopardize your health or ability to regain function, or cause uncontrolled pain, you can ask for an expedited review. Expedited external reviews are generally decided within 72 hours, and expedited internal and external review can run at the same time.
• 6. If the internal appeal is denied, file for independent external review. Reviewers who do not work for your insurer decide. Under the ACA this right applies to medical-necessity and experimental or investigational denials. Standard external review decisions generally come within about 45 days and are binding on the plan. Your denial letter must explain how to request it. Self-funded plans use either a state process or the HHS-administered federal external review process.
• 7. If you hit a wall, ask for help. Contact your state Department of Insurance or state Consumer Assistance Program for state-regulated plans, or the U.S. Department of Labor for ERISA employer plans. Nonprofit patient-advocacy and legal-aid groups can also assist.

You do not have to fight this alone

Free help exists at almost every step. Oncology social workers, hospital patient navigators, and financial navigators at your cancer center can screen you for assistance, help draft appeals, and set up payment plans, usually at no cost. Nonprofit groups such as Triage Cancer, the Patient Advocate Foundation, CancerCare, the Leukemia and Lymphoma Society, and Family Reach provide free navigation help and, in many cases, help with appeals and copay grants.

On the cost side, ask about manufacturer copay cards (for commercially insured patients), manufacturer patient assistance programs (for uninsured or underinsured patients), and independent copay foundations such as the PAN Foundation, HealthWell, and Good Days, which can often help Medicare patients where manufacturer cards cannot. Nonprofit hospitals are required under IRS Section 501(r) to have a written financial assistance policy, so it is always worth requesting that application. Our companion guide on [cancer treatment costs and how to reduce them](/costs) walks through these programs in more detail.

If your treatment is approved but the bills still look wrong, that is a separate and very common problem worth checking. Oncology billing is complex, and errors in drug units, infusion time, duplicate charges, facility fees, and out-of-network send-out labs happen. Compare your itemized bill against your insurer’s Explanation of Benefits, and treat anything that does not match as an error to question, not a debt to accept. See our guide on [checking cancer bills for errors](/medical-bill-help) for a line-by-line walkthrough. If reviewing a denial or a large cancer bill feels like too much on top of everything else, CareRoute’s Bill Defense service can review your bills and coverage denials and handle the back-and-forth with the provider and plan on your behalf, so you can focus on your treatment. You can learn more at [CareRoute Bill Defense](/bill-defense).

Frequently asked questions

Related resources